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Background and Purpose. Demographic changes will result in rapid growth of 
patients ≥90 years (nonagenarians), but little is known about outcomes in these 
patients after intravenous thrombolysis (IVT) for acute ischemic stroke. We aimed to 
assess safety and functional outcome in nonagenarians treated with IVT and to 
compare the outcomes with patients aged 80 to 89 years (octogenarians). 
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Methods. We analyzed prospectively collected data of 284 consecutive stroke patients 
≥80 years treated with IVT in seven Swiss stroke units. Presenting characteristics, 
favorable outcome (modified Rankin scale 0 or 1), mortality at 3 months and 
symptomatic intracranial hemorrhage (SICH) using the NINDS and SITS-MOST criteria 
were compared between nonagenarians and octogenarians. 
 
Results. As compared with octogenarians (n=238, mean age 83 years), nonagenarians 
(n=46, mean age 92 years) were more often women (70% vs. 54%, p=0.046) and had 
lower systolic blood pressure (161 mm Hg vs. 172 mm Hg, p=0.035). Patients ≥90 
years had less often a favorable outcome and a higher incidence of mortality than 
patients aged 80 to 89 years (14.3% vs. 30.2%, p=0.034 and 45.2% vs. 22.1%, 
p=0.002, respectively), while more nonagenarians than octogenarians experienced a 
SICH (SICHNINDS 13.3% vs. 5.9%, p=0.106; SICHSITS-MOST 13.3% vs. 4.7%, p=0.037). 
Multivariable adjustment identified age ≥90 years as an independent predictor of 
mortality (p=0.017). 
 
Conclusion. Our study suggests less favorable outcomes in nonagenarians as 
compared with octogenarians after IVT for ischemic stroke and demands a careful 
selection for treatment, unless randomized controlled trials yield more evidence for IVT 
in very old stroke patients. 
 
   3 
 
INTRODUCTION 1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
Age is the most important nonmodifiable risk factor for stroke and a major predictor of 
clinical outcome after ischemic stroke, with increased mortality and higher risk of 
intracranial hemorrhage by advancing age.1-2 In the elderly patients, evidence from 
randomized controlled trials for benefit of intravenous thrombolysis (IVT) with alteplase 
is scarce, as patients over 80 years of age were either underrepresented or excluded in 
these trials.3-4 Several observational studies reported on outcomes in patients ≥80 
years with ischemic stroke and suggested a potential benefit of IVT,5-7 but little is 
known about outcome specifically in nonagenarians. Nonetheless, demographic 
changes result in excessive growing of the “oldest-old” population. Thus, the number of 
nonagenarians will increase almost eight-fold to 57 million by 2050 worldwide.8 We 
therefore undertook this study to assess the rates of symptomatic intracranial 
hemorrhage (SICH), mortality and favorable outcome in nonagenarians treated with 
IVT for ischemic stroke and compared the data with outcomes in octogenarians.  
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PATIENTS AND METHODS 1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
As a joint initiative of seven stroke centers in Switzerland, we designed a study to 
compare the outcome in nonagenarians with octogenarians after IVT for ischemic 
stroke. All participating centers used IVT according to current guidelines.9 Neither 
center applied an upper age limit for IVT, because in Switzerland alteplase is licensed 
for ischemic stroke without age restrictions.7 Patients and relatives were informed about 
limited evidence for the effectiveness of alteplase in patients aged ≥80 years, however, 
and informed consent was obtained prior to treatment. A standardized form was used 
to collect data with pre-defined variables as it was also done in a previous study with 
similar methodology.10 We analyzed data of consecutive patients aged 80 years or 
older who were treated with intravenous alteplase for acute ischemic stroke between 
January 1, 2000, and December 31, 2008.  
The following variables were ascertained: age, gender, vascular risk factors 
according to pre-defined criteria,10 history of coronary artery disease, antithrombotic 
medication at stroke onset, baseline National Institutes of Health Stroke Scale (NIHSS) 
score, stroke etiology according to the Trial of ORG 10172 in Acute Stroke Treatment 
(TOAST)-criteria, time to treatment, blood pressure and blood glucose level obtained at 
admission. All patients treated with IVT were admitted to intermediate or intensive care 
units for at least 24 hours. All patients underwent brain imaging with computed 
tomography (CT) or magnetic resonance imaging (MRI) 24 to 48 hours after IVT and in 
any case of clinical deterioration. Clinical outcome was assessed by outpatient visits or 
structured telephone interviews using the modified Rankin Scale (mRS) score at 3 
months. 
The primary outcome measures were favorable outcome, defined as mRS score 
0-1 and mortality at 3 months. Secondary, we assessed the rate of SICH by applying 
the definition from the National Institute of Neurological Disorders and Stroke trial 
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(SICHNINDS).3 In addition, we also used the more conservative definition from the the 
Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SICHSITS-MOST).11  
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
 
Statistical analysis 
Normally distributed data were expressed as meanstandard deviation (SD) and 
compared using unpaired, two-tailed t-test. The two groups (nonagenarians and 
octogenarians) were compared using Mann Whitney U test for continuous variables 
and a chi-square or a Fisher's exact test (the latter if some expected counts in the two-
by-two table were less than 5) for binary variables. Multiple logistic regression analyses 
were performed to assess the joint effects of age and stroke risk factors on the 
outcome parameters SICH, mortality and favorable outcome. In a first step, the 
influence of every single potential predictor on the outcomes was evaluated using 
univariate logistic regression analyses. The parameters examined were baseline 
NIHSS score, time to treatment, systolic and diastolic blood pressure, blood glucose 
level on admission (continuous variables), age (80 to 89 years vs. 90 to 99 years) 
patients gender, arterial hypertension, smoking, diabetes mellitus, 
hypercholesterolemia, coronary heart disease and antithrombotic medication with 
antiplatelets or anticoagulants at stroke onset (categorical variables). In a second step, 
a multivariate logistic regression analysis was performed, including all potential 
predictors with a p-value <0.2 from univariate analyses into the model. Significance 
was declared at p<0.05 level.  
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RESULTS 1 
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Forty-six nonagenarians (mean age 92, range 90 to 99 years) and 238 octogenarians 
(mean age 83, range 80 to 89 years) were eligible for this study. As compared with 
their counterparts, nonagenarians were more often women (70% vs. 54%, p=0.046), 
had a lower systolic blood pressure (160 mm Hg vs. 172 mm Hg, p=0.035) and tended 
to have slightly more severe strokes by a mean NIHSS score of 1.5 points, which was 
not significant however (Table 1). Nine of 46 (19.6%) nonagenarians and 52 of 238 
(21.8%) octogenarians were treated beyond the 3-hour wime window (p=0.730), while 
ten of 237 (4.2%) octogenarians and none of nonagenarians were treated with oral 
anticoagulants at stroke onset (p=0.375). Time to treatment and other vascular risk 
factors did not differ significantly between the two groups (Table 1). 
At three months, six of 42 nonagenarians reached a favorable outcome (Table 2). In 
comparison, the frequency of favorable outcome in octogenarians was significantly 
higher (30.2% vs. 14.3%, p=0.034). Logistic regression analyses identified NIHSS 
score (p<0.001), antiplatelet medication (p=0.003), diabetes mellitus (p=0.006) and 
anticoagulants (p=0.007) to be independently associated with clinical outcome at three 
months, while the association with age ≥90 years was no longer significant (p=0.147).  
Within the nonagenarian group, six out of 10 (60%; 95% CI 23.1-96.9) men 
experienced a favorable outcome, whereas all 32 (100%) women had an unfavorable 
outcome (p<0.001). Furthermore, nonagenarians with a favorable outcome had less 
severe strokes (mean NIHSS score 11 vs. 16 points, p=0.028), whereas no association 
was identified with time to treatment and the age of nonagenarians. Mortality in 
nonagenarians was significantly higher as compared with octogenarians (45.2% vs. 
22.1%, p=0.002) (Table 2). After multivariable adjustment, independent predictors of 
mortality were age ≥90 years (p=0.017), anticoagulants (p=0.049) and the NIHSS score 
(p<0.001).  
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 Classification of SICH was available in 45 of 46 nonagenarians. Six patients aged 
≥90 years experienced a SICH (according to NINDS and SITS-MOST criteria), five of 
them were fatal and one caused severe disability (mRS 5). Compared with 
octogenarians, the risk of SICH in nonagenarians was about two-fold higher. The 
difference was statistically significant by using the SITS-MOST criteria (13.3% vs. 
4.7%, p=0.037), but not the NINDS criteria (13.3% vs. 5.9%, p=0.106) (Table 2). 
Multivariate analyses did not identify an independent predictor of SICH. In 
nonagenarians, 5 of 6 (83.3%) SICH were fatal. In comparison, 5 of 14 (35.7%) SICH 
were fatal in octogenarians, but the difference was statistically not significant (p=0.141). 
Fatal SICH in nonagenarians (5/19, 26.3%) tended to account more often for mortality 
as compared with octogenarians (5/52, 9.6%). The difference was statistically not 
significant (p=0.118). 
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This multicenter observational study assessed clinical outcomes in stroke patients ≥90 
years treated with IVT and suggests poor outcomes for this age group: about one out of 
seven patients reached a favorable outcome and nearly half of the population died 
within the first three months after stroke, while 13% of patients experienced a SICH, all 
of them causing either death or severe disability. Nonagenarians had an about two-fold 
higher risk for unfavorable outcome, mortality and SICH as compared with 
octogenarians.  
Only 6 of 42 (14%) nonagenarians reached a favorable outcome at three months, 
while clinical outcome was favorable in 30% of octogenarians (p=0.034). Our results 
are in concordance with the study from Mayo Clinics that reported favorable outcome in 
2 of 20 (10%) alteplase treated nonagenarians at 30 days.12 In contrast, the recently 
published post-hoc analysis of the Canadian Activase for Stroke Effectiveness Study 
(CASES) showed similar outcomes in nonagenarians at 30 days as compared with 
octogenarians (30% vs. 26%).13 In our population of nonagenarians, age, stroke 
severity and time to treatment were similar to those observed in the CASES registry 
and thus do not explain the different outcomes. Comorbidities (e.g. previous stroke, 
cancer, dementia, congestive heart failure) and pre-stroke disability might have differed 
between the two populations as a probable explanation. Another finding of our study is 
the worse clinical outcome in women ≥90 years as compared to their male 
counterparts. This may have implications for clinical practice, since women comprise 
higher population proportions in advanced age and the female-male ratio will 
dramatically increase by every decade of age in future.8 However, the wide 95% CI 
preclude any definite conclusion. 
 The 3-month mortality in nonagenarians treated with IVT reached 45%, which was 
two-fold higher as compared with octogenarians. Our finding is in concordance with 
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three recent studies that reported a 3-month mortality of 51% to 59% in stroke patients 
≥90 years undergoing IVT.12-14 The higher incidence of SICH in nonagenarians may 
have contributed to the difference in mortality between the two populations. 
Furthermore, age is an independent predictor of mortality and studies on IVT reported 
an increased 3-month mortality with older age up to 40 % in stroke patients ≥80 
years.15 The same is true for elderly stroke patients who are not treated with IVT.16 The 
3-month mortality of 45% reported in stroke patients ≥80 years without thrombolysis is 
consistent with that observed in nonagenarians from our study.17 Finally, mean NIHSS 
score in nonagenarians was by 1.5 points higher than in octogenarians and multivariate 
analyses identified NIHSS score as an independent predictor of mortality. These data 
suggest that, rather than IVT alone, other factors such as older age, comorbid 
conditions and stroke severity may have been substantially related to the high mortality 
in nonagenarians which was consistent with the natural history reported in this age 
group.  
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 The rate of SICH in nonagenarians was higher as compared with octogenarians, 
and the difference was significant according to the SITS-MOST criteria, but not 
according to the NINDS criteria. Age ≥90 years did not predict SICH after multivariate 
logistic regression analyses, but all SICH in this age category were severe, and most of 
them leading to death. In comparison, data from CASES registry showed a relative risk 
of 1.7 for SICH in nonagenarians as compared with octogenarians after IVT, which was 
not statistically significant. The higher incidence of SICH in patients ≥90 years may be 
explained by impaired ability to clear alteplase and higher frequency of cerebral 
amyloid angiopathy and leukoaraiosis by advancing age, that might be more 
pronounced in nonagenarians than in octogenarians. In contrast, the risk of SICH in 
octogenarians was comparable to that of the NINDS trial and is line with the findings of 
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a systematic review and a recently published large-scale study that reported a similar 
risk of SICH in stroke patients aged ≥80 and <80 years of age.14, 18  
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This study has some limitations. It is a multi-center, observational study performed in 
clinical setting, and IVT was performed at the discretion of the treating physicians. 
Thus, a selection bias is likely and baseline characteristics such as age, stroke severity, 
blood pressure, glycemia and imaging findings might have influenced the decision 
whether to administer IVT or not. Some baseline variables that could potentially 
influence stroke outcome such as previous stroke in past medical history, pre-stroke 
disability and atrial fibrillation were not available for analysis. Furthermore, the cohort 
size of nonagenarians was small, the possibility of a type 2 error must be admitted. 
Finally, there is no age-matched control group and the assessment of the mRS score at 
3 months was not blinded to the clinical condition of the patients during the hospital 
stay and at discharge.  
In conclusion, the observational design of this study does not allow us to judge the 
efficacy and safety of IVT in nonagenarians with ischemic stroke. Nonetheless, our 
data suggest less frequent favorable outcomes, higher mortality and more frequent 
SICH in nonagenarians as compared with octogenarians. These findings may be useful 
for accurate adjusting of patient and family expectations. Furthermore, a careful 
selection of patients ≥90 years for IVT is needed in view of less favorable outcomes in 
this age population. Randomized controlled trials such as the ongoing International 
Stroke Trial (IST)-3 would yield more evidence on the balance of risk and benefit of IVT 
in stroke patients aged 90 years and older,19 whereas our study could hopefully 
stimulate further research interest in this progressively growing very old patients 
population. 
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Table 1. Baseline Characteristics of Nonagenarians and Octagenarians Treated with Intravenous Thrombolysis 
 
 
 
Nonagenarians (n=46) 
 
Octagenarians (n=238) 
 
P Value 
Male sex [%] 14/46 (30.4) 110/237 (46.4)  0.046 
Hypertension [%] 39/46 (84.8) 193/238 (81.1) 0.554 
Current smoking [%] 3/45 (6.7)  29/238 (12.2) 0.284 
Diabetes mellitus [%] 5/45 (11.1) 33/238 (13.9) 0.619 
Hypercholesterolemia [%] 12/44 (27.3)  93/235 (39.6 ) 0.122 
Antiplatelet medication at stroke onset [%] 24/46 (52.2) 107/237 (45.1) 0.382 
Anticoagulation at stroke onset [%] 0/46 (0)  10/237 (4.2) 0.375† 
Coronary artery disease [%] 13/45 (28.9) 50/238 (21.0) 0.244 
Mean NIHSS score ± SD 14.4 ± 6.7 12.9 ± 5.9 0.126* 
Time to treatment ± SD  148.8 ± 51.1 159.6 ± 40.7 0.116* 
Mean systolic blood pressure ± SD [mm Hg] 161.1 ± 28.7  172.0 ± 25.9  0.035* 
Mean diastolic blood pressure ± SD  [mm Hg] 85.7 ± 20.8  90.1 ± 18.0  0.175* 
Mean blood glucose ± SD [mmol/L] 7.0 ± 2.9  7.1 ± 2.3  0.842* 
Cause of stroke   
     Large artery atherosclerosis [%] 10/45 (22.2) 79/238 (33.2) 
     Cardiac embolism [%] 22/45 (48.9) 80/238 (33.6) 
     Small artery disease [%] 2/45 (4.4) 13/238 (5.5) 
     Other determined etiology [%] 0/45 (0) 4/238 (1.7) 
     Undetermined etiology [%] 11/45 (24.4) 62/238 (26.1) 
0.312 
 
NIHSS denotes National Institutes of Stroke Scale, IVT intravenous thrombolysis, and SD standard deviation 
P-values apply to chi-square tests unless otherwise indicated  
* t-test, † Fisher exact test
Table 2. Favorable Outcome, Mortality and Symptomatic Intracranial Hemorrhage in Nonagenarians and Octogenarians Treated With Intravenous Thrombolysis 
 
 
 
 
 
 
Nonagenarians 
n/N, % (95% CI) 
Octogenarians 
n/N, % (95% CI) 
P  Value  
Univariate 
P  Value  
Logistic Regression 
Favorable Outcome 
6/42  
14.3 (3.2-25.3) 
71/235  
30.2 (24.3-36.1) 0.034 0.130 
Mortality 
19/42  
45.2 (29.5-60.9) 
52/235  
22.1 (16.8-27.5) 0.002 0.017 
Symptomatic ICH 
 
 
   
      per NINDS 
6/45  
13.3 (3.0-23.7) 
14/236  
5.9 (2.9-9-0) 0.106* 0.130 
      per SITS-MOST 
6/45  
13.3 (3.0-23.7) 
11/236 
4.7 (2.0-7.4) 0.037* 0.138 
 
 
 
 
ICH denotes intracranial hemorrhage, NINDS National Institute of Neurological Disorders and Stroke, SITS-MOST Safe Implementation of Thrombolysis in Stroke-Monitoring Study 
P-values apply to chi-square tests unless otherwise indicated 
* Fisher exact test 
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